A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...

The results of the clinical trial mark a setback for the Swiss pharmaceutical company, which saw in the drug, giredestrant, a candidate to become a blockbuster treatment.

The alternative medicine industry is expanding rapidly, fueled in large part by the surge of health-related content on social ...

Roche said the late-stage trial did not provide reliable evidence that ​the drug's use in combination with Pfizer's Ibrance ...

A one‑year course of T‑DM1 offers excellent cancer‑free survival for early HER2‑positive breast cancer, with far less nerve ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

News, features, and commentary about cancer-related issues ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

New research suggests childhood cancer survivors may experience accelerated biological aging from treatments, potentially ...

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

Crucially, in their analysis, the researchers excluded the use of PPIs in one year before stomach cancer diagnoses. That's because stomach cancer symptoms can often show up as pain, reflux and ...